日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Targeting PIKfyve-driven lipid metabolism in pancreatic cancer.

靶向 PIKfyve 驱动的胰腺癌脂质代谢

Cheng Caleb, Hu Jing, Mannan Rahul, He Tongchen, Bhattacharyya Rupam, Magnuson Brian, Wisniewski Jasmine P, Peters Sydney, Karim Saadia A, MacLean David J, Karabürk Hüseyin, Zhang Li, Rossiter Nicholas J, Zheng Yang, Xiao Lanbo, Li Chungen, Awad Dominik, Mahapatra Somnath, Bao Yi, Zhang Yuping, Cao Xuhong, Wang Zhen, Mehra Rohit, Morlacchi Pietro, Sahai Vaibhav, Pasca di Magliano Marina, Shah Yatrik M, Weisman Lois S, Morton Jennifer P, Ding Ke, Qiao Yuanyuan, Lyssiotis Costas A, Chinnaiyan Arul M

Targeting histone H2B acetylated enhanceosomes via p300/CBP degradation in prostate cancer

通过p300/CBP降解靶向组蛋白H2B乙酰化增强子在前列腺癌中的应用

Jie Luo # ,Zhixiang Chen # ,Yuanyuan Qiao # ,Jean Ching-Yi Tien ,Eleanor Young ,Rahul Mannan ,Somnath Mahapatra ,Rupam Bhattacharyya ,Lanbo Xiao ,Tongchen He ,Sanjana Eyunni ,Yuping Zhang ,Yang Zheng ,Fengyun Su ,Xuhong Cao ,Rui Wang ,Yunhui Cheng ,Rithvik Seri ,James George ,Miriam Shahine ,Stephanie J Miner ,Matthew G Rees ,Melissa M Ronan ,Jennifer A Roth ,Ulka Vaishampayan ,Mi Wang ,Shaomeng Wang ,Abhijit Parolia ,Arul M Chinnaiyan

Neoadjuvant chemotherapy or chemoradiotherapy plus sintilimab versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a study protocol of a multicentre, randomised, controlled, phase III trial (SCIENCE study)

新辅助化疗或放化疗联合信迪利单抗与新辅助放化疗治疗局部晚期食管鳞状细胞癌:一项多中心、随机、对照 III 期试验的研究方案(SCIENCE 研究)

He, Wenwu; Bai, Hansong; Lv, Jiahua; Tang, Peng; Hu, Tongchen; Zhou, Haining; Xiao, Wenguang; Peng, Lin; Liu, Guangyuan; Wang, Kangning; Fang, Qiang; Qi, Yunxiang; Liang, Long; Zheng, Xiumei; Qing, Haomiao; Chen, Yungchang; Zhou, Yehan; Xie, Wenjing; Han, Yongtao; Leng, Xuefeng

Targeting the mSWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies.

靶向 POU2F-POU2AF 转录因子驱动的恶性肿瘤中的 mSWI/SNF 复合物

He Tongchen, Xiao Lanbo, Qiao Yuanyuan, Klingbeil Olaf, Young Eleanor, Wu Xiaoli S, Mannan Rahul, Mahapatra Somnath, Redin Esther, Cho Hanbyul, Bao Yi, Kandarpa Malathi, Ching-Yi Tien Jean, Wang Xiaoju, Eyunni Sanjana, Zheng Yang, Kim NamHoon, Zheng Heng, Hou Siyu, Su Fengyun, Miner Stephanie J, Mehra Rohit, Cao Xuhong, Abbineni Chandrasekhar, Samajdar Susanta, Ramachandra Murali, Dhanasekaran Saravana M, Talpaz Moshe, Parolia Abhijit, Rudin Charles M, Vakoc Christopher R, Chinnaiyan Arul M

Discovery of LLC0424 as a Potent and Selective in Vivo NSD2 PROTAC Degrader

发现 LLC0424 是一种有效且选择性的体内 NSD2 PROTAC 降解剂

Lianchao Liu, Abhijit Parolia, Yihan Liu, Caiyun Hou, Tongchen He, Yuanyuan Qiao, Sanjana Eyunni, Jie Luo, Chungen Li, Yongxing Wang, Fengtao Zhou, Weixue Huang, Xiaomei Ren, Zhen Wang, Arul M Chinnaiyan, Ke Ding

Targeting the mSWI/SNF Complex in POU2F-POU2AF Transcription Factor-Driven Malignancies

针对 POU2F-POU2AF 转录因子驱动的恶性肿瘤中的 mSWI/SNF 复合物

Tongchen He, Lanbo Xiao, Yuanyuan Qiao, Olaf Klingbeil, Eleanor Young, Xiaoli S Wu, Rahul Mannan, Somnath Mahapatra, Sanjana Eyunni, Jean Ching-Yi Tien, Xiaoju Wang, Yang Zheng, NamHoon Kim, Heng Zheng, Siyu Hou, Fengyun Su, Stephanie J Miner, Rohit Mehra, Xuhong Cao, Chandrasekhar Abbineni, Susanta

NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis

NSD2是AR/FOXA1新增强子复合物促进前列腺肿瘤发生所必需的亚基。

Parolia, Abhijit; Eyunni, Sanjana; Verma, Brijesh Kumar; Young, Eleanor; Liu, Lianchao; George, James; Aras, Shweta; Das, Chandan Kanta; Mannan, Rahul; Rasool, Reyaz Ur; Luo, Jie; Carson, Sandra E; Mitchell-Velasquez, Erick; Liu, Yihan; Xiao, Lanbo; Gajjala, Prathibha R; Jaber, Mustapha; Wang, Xiaoju; He, Tongchen; Qiao, Yuanyuan; Pang, Matthew; Zhang, Yuping; Alhusayan, Mohammed; Cao, Xuhong; Tavana, Omid; Hou, Caiyun; Wang, Zhen; Ding, Ke; Chinnaiyan, Arul M; Asangani, Irfan A

p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer

p300/CBP 降解是关闭前列腺癌中活性 AR 增强体所必需的

Jie Luo, Zhixiang Chen, Yuanyuan Qiao, Jean Ching-Yi Tien, Eleanor Young, Rahul Mannan, Somnath Mahapatra, Tongchen He, Sanjana Eyunni, Yuping Zhang, Yang Zheng, Fengyun Su, Xuhong Cao, Rui Wang, Yunhui Cheng, Rithvik Seri, James George, Miriam Shahine, Stephanie J Miner, Ulka Vaishampayan, Mi Wang,

Targeting PIKfyve-driven lipid homeostasis as a metabolic vulnerability in pancreatic cancer

以 PIKfyve 驱动的脂质稳态作为胰腺癌代谢脆弱性的目标

Caleb Cheng, Jing Hu, Rahul Mannan, Rupam Bhattacharyya, Nicholas J Rossiter, Brian Magnuson, Jasmine P Wisniewski, Yang Zheng, Lanbo Xiao, Chungen Li, Dominik Awad, Tongchen He, Yi Bao, Yuping Zhang, Xuhong Cao, Zhen Wang, Rohit Mehra, Pietro Morlacchi, Vaibhav Sahai, Marina Pasca di Magliano, Yatr

Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapy

靶向脂质激酶 PIKfyve 可上调 MHC I 类的表面表达,从而增强癌症免疫疗法

Yi Bao, Yuanyuan Qiao, Jae Eun Choi, Yuping Zhang, Rahul Mannan, Caleb Cheng, Tongchen He, Yang Zheng, Jiali Yu, Mahnoor Gondal, Gabriel Cruz, Sara Grove, Xuhong Cao, Fengyun Su, Rui Wang, Yu Chang, Ilona Kryczek, Marcin Cieslik, Michael D Green, Weiping Zou, Arul M Chinnaiyan